
Targacept Inc Profile last edited on: 6/15/2021
CAGE: 4SEZ2
UEI: ER6HGKX8AFN5
Business Identifier: Neuronal nicotinic receptor technology Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
100 North Main Street Suite 1510
Winston-Salem, NC 27101
Winston-Salem, NC 27101
(336) 480-2100 |
jo.peay@targacept.com |
www.targacept.com |
Location: Single
Congr. District: 05
County: Forsyth
Congr. District: 05
County: Forsyth
Public Profile
Initially launched by Rhone-Poulenc Rorer Inc. and RJR Nabisco Inc., Targacept was set up to work on compounds interactive with human nicotinic receptors. The declared objective was to develop and commercialize new drugs to treat Alzheimer's and Parkinson's diseases. In August 2015, Taracept did a reverse merger with Calatyst Biosciences Inc - also SBIR Involved with the combined entity retaining the Catalyst name replacing symbol TRGT by Catalyst symbol - CBIO providing partner Pfizer a shorcut to NASDAQ. With decades of research at R.J. Reynolds Tobacco Company (RJRT) into the chemistry and biology of nicotine resulting in hundreds of scientific papers and abstracts, many focused on neuronal nicotinic receptors (NNRs), a unique class of molecular targets in the body that maintain and adjust nervous system activity. The findings from RJRTs research staff, as well as numerous investigations reported in the scientific literature into the biological effects of nicotine, suggested a role for NNRs in the treatment of human disease and commercial potential for RJRs research. Targacept, Inc. was established as a wholly owned subsidiary of RJRT and was then spun out in August 2000. The spin-out allowed Targacept to combine its expertise in discovering new therapeutic agents with investors that have experience in the pharmaceutical business. Products in place to date are Inversine® (mecamylamine HCl) for the treatment of moderately severe to severe essential hypertension and for uncomplicated cases of malignant hypertension
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : TRGTIP Holdings
150-249Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2003 | 1 | NSF | $99,959 | |
Project Title: The Development of Self-Organizing Maps for Drug Discovery |
Key People / Management
Stephen A H Hill -- Chief Exec. Officer, Pres And Director
J Donald Debethizy -- former President
Jeffrey Schmitt
J Donald Debethizy -- former President
Jeffrey Schmitt